Bacteriophage Esc-COP-7 for Targeting Pathogenic E. coli
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating pathogenic Escherichia coli infections in livestock are inadequate due to the increasing resistance to antibiotics and the need for more specific and environmentally friendly alternatives.
Innovation Solution
A Myoviridae bacteriophage Esc-COP-7, isolated from nature and characterized by a specific genome sequence, is used as an active ingredient in compositions for preventing and treating pathogenic Escherichia coli infections, offering high specificity and safety by targeting only the pathogenic bacteria without affecting commensal bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used for preventing and treating pathogenic Escherichia coli infections, then the treatment effectiveness is improved, but antibiotic-resistant bacteria increase and environmental pollution occurs
Solution Approach 1:
The patent uses bacteriophage Esc-COP-7 as an intermediary agent to treat pathogenic Escherichia coli infections. The bacteriophage specifically infects and kills target bacteria through biological mechanisms (injection of genetic material, replication, and lysis) rather than chemical antibiotics, thereby maintaining treatment effectiveness while avoiding antibiotic resistance and environmental pollution. The bacteriophage acts as a mediator that transfers the therapeutic effect without the harmful side effects of conventional antibiotics.
Solution Approach 2:
The patent changes the fundamental parameter of the treatment mechanism from chemical (antibiotics) to biological (bacteriophage). This parameter change allows the treatment to be highly specific to pathogenic Escherichia coli strains while preserving commensal bacteria and the environment. The bacteriophage's specificity is determined by its receptor binding properties, which naturally select for target bacteria without broad-spectrum effects.
2Reliability
If conventional antibiotics are used, then bacterial infections are treated, but commensal bacteria are also affected causing disturbance of normal flora
Solution Approach 1:
The patent applies the principle of local quality by making the treatment highly specific to pathogenic Escherichia coli through the bacteriophage's receptor-specific binding. The bacteriophage Esc-COP-7 is engineered or selected to recognize and bind to specific surface structures (such as O-antigens or other outer membrane proteins) that are present on pathogenic strains but absent or different in commensal bacteria. This localized specificity ensures that only the target pathogenic bacteria are infected and killed, while commensal bacteria remain unaffected and the normal flora is preserved.
3Object-affected harmful factors
If bacteriophages are used as an alternative to antibiotics, then environmental friendliness is improved, but the specificity limits the number of bacteriophage types that can infect a specific bacterium
Solution Approach 1:
The patent applies segmentation by dividing the broad spectrum of Escherichia coli into specific pathogenic strains that can be targeted by the bacteriophage Esc-COP-7. Rather than attempting to create a single universal bacteriophage that infects all bacteria, the approach segments the problem into strain-specific treatments. The bacteriophage is designed or selected to target specific pathogenic strains (such as O157:H7 or other Enterohemorrhagic E. coli strains) with high specificity, allowing for precise treatment of different pathogenic variants while maintaining environmental friendliness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacteriophage composition effectively inhibits and kills pathogenic Escherichia coli, reducing disease severity and mortality in livestock, while being environmentally friendly and minimizing side effects on normal flora.
Implementation Method 1
bacteriophages are very small microorganisms infecting bacteria... Once a bacteriophage infects bacteria, the bacteriophage is proliferated inside the bacterial cell
Implementation Method 2
the bacteriophage is proliferated inside the bacterial cell. After proliferation, the progeny of the bacteriophage destroy the bacterial cell wall
Implementation Method 3
the progeny of the bacteriophage destroy the bacterial cell wall and escapes from the host bacteria
Data Source
AI summary
The present invention relates to a Myoviridae bacteriophage ESC-COP-7 (accession number KCTC 13130BP) isolated from nature, and a method for preventing and treating infections from pathogenic Escherichia coli by means of a composition containing the Myoviridae bacteriophage ESC-COP-7 as an active ingredient, the Myoviridae bacteriophage ESC-COP-7 being characterized by having the capability to specifically kill Escherichia coli, and genome expressed by the SEQ ID 1.